What question did this study set out to answer?

Establish practical clinical guidance for physicians administering emicizumab prophylaxis in patients with haemophilia A across diverse clinical scenarios.

June 25, 2020HämostaseologieOpen Access

Practical Guidance of the GTH Haemophilia Board on the Use of Emicizumab in Patients with Haemophilia A

View Full Paper

Ask AI

Bookmark

Establish practical clinical guidance for physicians administering emicizumab prophylaxis in patients with haemophilia A across diverse clinical scenarios.
Conducted a systematic literature search in PubMed supplemented by clinical expert experience within the German, Austrian, Swiss Society for Thrombosis and Haemostasis Research (GTH).
Formulated, debated, and revised clinical recommendations using a consensus approach analogous to the Delphi method among members of the GTH Haemophilia Board.
Concomitant management of bleeds or surgery using factor VIII or recombinant activated factor VII has not been associated with reported thromboembolic complications.
Activated prothrombin complex concentrate doses greater than 100 U/kg for over 24 hours must be avoided to mitigate high risks of thrombosis and thrombotic microangiopathy.
Treatment should occur in expert centres with access to specialized laboratory assays capable of accurately measuring emicizumab concentrations, factor VIII replacement, and inhibitor levels.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Expert consensus guideline outlines management protocols for emicizumab in haemophilia A, highlighting risk mitigation strategies for thrombotic complications.

Cite This Study

Holstein et al. (2020) studied this question.

synapsesocial.com/papers/6aae04adf336864a9837d130 https://doi.org/10.1055/a-1127-6476

View Full Paper

Ask AI

Bookmark

Implication

Expert consensus guideline outlines management protocols for emicizumab in haemophilia A, highlighting risk mitigation strategies for thrombotic complications.

Practical Guidance of the GTH Haemophilia Board on the Use of Emicizumab in Patients with Haemophilia A

Key Points

Discussion

Implication

Cite This Study

Practical Guidance of the GTH Haemophilia Board on the Use of Emicizumab in Patients with Haemophilia A

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider